BioMarin announced a dosing pause for subsets of patients in two Phase 2 trials of Voxzogo after independent studies flagged hip‑related adverse events—specifically cases of slipped capital femoral epiphysis (SCFE). The company said it will halt dosing in affected cohorts while it investigates the safety signal and consults regulators and clinical experts. BioMarin emphasized that patient safety is the priority and that trial protocols will be adjusted as needed. The pause could delay development timelines and will draw scrutiny to benefit‑risk assessments for the program if the hip events are confirmed as drug‑related.